Cannabinoid dosing regime for dermatitis and inflammatory skin conditions

Abstract

A treatment regime for use in the treatment or prevention of dermatitis and inflammatory skin conditions, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

1 .- 32 . (canceled) 
     
     
         33 . A method for treating a subject suffering from dermatitis or an inflammatory skin condition, comprising:
 administering a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabidiol, 85% w/w and 95% w/w of hexamethyldisiloxane, octamethyltrisiloxane or combinations thereof, and between 1% w/w and 10% w/w of a residual solvent that is less volatile than hexamethyldisiloxane, octamethyltrisiloxane or combinations thereof such that less than 5% of the residual solvent evaporates at skin temperature over 24 hours and wherein the residual solvent is selected from fatty acids, fatty acid alcohols, fatty alcohols, glycols or alkanes, or ethers of any of these, or combinations thereof, wherein the cannabidiol is dissolved in the liquid or gel composition, and the total daily dose applied to the skin is between mg and 2000 mg cannabidiol   
     
     
         34 . The method of  claim 33 , wherein the topical composition is administered to the skin between 1 and 5 times per day. 
     
     
         35 . The method of  claim 33 , wherein between 20 mg and 400 mg of cannabidiol is applied per administration. 
     
     
         36 . The method of  claim 33 , wherein the topical composition comprises 2%-7% or 4% w/w cannabidiol. 
     
     
         37 . The method of  claim 33 , wherein the topical composition comprises 1-10% wt/wt C2-C 6  alcohol. 
     
     
         38 . The method of  claim 33 , wherein the topical composition comprises 85% w/w and 95% w/w hexamethyldisiloxane. 
     
     
         39 . The method of  claim 33 , wherein the residual solvent is selected from the group consisting of: alkyl polypropylene glycol, polyethylene glycol ether, oleyl alcohol, isostearyl alcohol, octyldodecyl alcohol, 2-hexyl decyl alcohol, isohexadecane and combinations thereof. 
     
     
         40 . The method of  claim 33 , wherein 180 mg of cannabidiol is applied per day. 
     
     
         41 . The method of  claim 33 , wherein the subject is suffering from dermatitis. 
     
     
         42 . The method of  claim 33 , wherein the subject is suffering from atopic dermatitis. 
     
     
         43 . The method of  claim 33 , wherein the patient is suffering from rosacea.